Drugs / SIGX1094R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06739291 | Dec 2024 → Oct 2026 expected | cancer | Signet Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIGX1094R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06739291 ↗ |
| Route | Oral | “orally administered once daily” NCT06739291 ↗ |